Intravenous immunoglobulins in neurological disorders: safety issues

Area of Science:

• Immunology and Pharmacology
• Therapeutic Applications of Immunoglobulins

Background:

• Intravenous immunoglobulin (IVIg) is used for antibody deficiency and autoimmune diseases.
• Dosage varies significantly: 400 mg/kg/month for antibody replacement versus 1-2 g/kg for autoimmune conditions.
• Off-label use of IVIg is common, necessitating thorough risk-benefit evaluations.

Purpose of the Study:

• To review the established indications and common off-label uses of IVIg.
• To categorize and discuss adverse events associated with IVIg therapy.
• To emphasize the importance of risk-benefit assessment in IVIg treatment.

Main Methods:

• Literature review of IVIg indications and adverse events.
• Analysis of reported complications, including inflammatory, infectious, renal, and thromboembolic events.
• Discussion of risk factors and potential mechanisms for severe adverse events.

Main Results:

• Early inflammatory reactions occur in 10%-85% of patients, manageable by adjusting infusion rates.
• Viral safety of IVIg products is now considered high, with historical transmission issues resolved.
• Rare but severe complications include renal issues (linked to certain excipients) and thromboembolic events (associated with high-dose, rapid infusions).

Conclusions:

• IVIg is a valuable therapeutic agent, but its use requires careful consideration of potential risks.
• Monitoring for renal and thromboembolic complications is essential, particularly in high-risk patients and with high-dose regimens.
• Ongoing vigilance and adherence to established guidelines are necessary for safe and effective IVIg utilization.